Genmab — August 2018
-
men jeg kan godt forstå, at I tænker at en omfattende strategi, hvor GEN selv vil bringe omfattende programmer til markedet er kortsigtet
-
Altså vi har en forward p/e for 2019 på 27-28 stykker lige nu. Og det er selvom Dara næste år er langt fra peaksale.
-
Beklager Jørgen Varnæs 19:13. Du har selvfølgelig ret
-
GeorgeBest and others thanks for your views. I also have a positive view on Genmab, but do recognize its difficult to hit multiple homeruns. I have trust in Jan, especially since interests are aligned. Not so happy that David is selling his shares, although at least (as making up from your comments) he is doing it consistently. Have a good evening.
-
Jamen vi har jo forskellige forståelser af situationen - hvis der virkelig er hold I knock-your-socks-off, så kan jeg ikke se begrundelsen for at investere i kompetencer, som hverken giver ekstraordinære afkast, basis for udvikling af kernekompetencer, eller danner nogen form for konkurrencefordel ifht konkurrenterne
-
God morgen
-
God morgen
-
Sequencing Through Multiple Lines of Therapy https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/sequencing-through-multiple-lines-of-therapy
-
Daratumumab in Primary Effusion Lymphoma
https://www.nejm.org/doi/full/10.1056/NEJMc1806295 -
Is immunotherapy cost-effective? http://www.oncologytube.com/video/is-immunotherapy-cost-effective/10004937
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind